Abstract：【Objective】 To explore the correlation between serum levels of Galactin-3 (Gal-3), Visfatin, and Chemerin and recurrence after first catheter radiofrequency ablation in patients with atrial fibrillation.【Methods】 A total of 184 patients with atrial fibrillation admitted to our hospital from August 2019 to August 2021 were selected. All patients underwent radiofrequency ablation treatment after admission. They were divided into a recurrence group (n=53) and a non recurrence group (n=131) based on whether they recurred within 6 months after surgery. We compared two clinical data sets and serum levels of Chemerin, Gal-3, and Visfatin before and 1 month after surgery, and analyzed the correlation and predictive value of these indicators with postoperative recurrence of atrial fibrillation at 1 month after surgery.【Results】 The proportion of recurrent group, concomitant hypertension, coronary heart disease, and left atrial volume index (LAVI) were higher than those of the non recurrent group, and the left ventricular ejection fraction (LVEF) was higher than those of the non recurrent group, with statistical significance (P<0.05). The serum levels of Gal-3, Visfatin, and Chemerin in the recurrent group were higher than those in the non recurrent group before and 1 month after surgery, with statistical significance (P<0.05). Logistic regression analysis showed that serum Gal-3, Visfatin, and Chemerin levels at one month post surgery were independent risk factors for postoperative atrial fibrillation recurrence (P<0.05). The risk of postoperative atrial fibrillation recurrence in patients with high levels of Gal-3, Visfatin, and Chemerin was 4.076 times, 2.847 times, and 6.272 times higher than that in patients with low levels (P<0.05).【Conclusion】 Serum Gal-3, Visfatin, and Chemerin are closely related to postoperative recurrence in patients with atrial fibrillation after the first radiofrequency ablation, which can predict the risk of postoperative recurrence in patients early and help clinical physicians formulate targeted treatment plans to reduce recurrence rates.
张莉侠, 董锦丽. Chemerin、Gal-3、Visfatin与房颤患者首次导管射频消融术后复发的相关性[J]. 医学临床研究, 2024, 41(1): 18-21.
ZHANG Lixia, DONG Jinli. The Correlation between Chemerin, Gal-3, Visfatin and Recurrence after First Catheter Radiofrequency Ablation in Patients with Atrial Fibrillation. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 18-21.
[1] 李慧英,刘青,魏晓明,等.外周血CⅠCP、NLR及鸢尾素在心房颤动合并心力衰竭患者中的表达及诊断价值[J].国际检验医学杂志,2022,43(14):1689-1693. [2] 徐尧,蔡衡,李洪仕.射频消融在心房颤动伴射血分数降低心力衰竭患者中的治疗价值的荟萃分析[J].中国心血管杂志,2022,27(1):66-70. [3] 卢昊阳,赵韧,卢家忠,等.血浆大内皮素1和白细胞介素17A及左心耳体积与心房颤动经射频消融术后复发的相关性[J].中华老年心脑血管病杂志,2022,24(7):705-708. [4] WANG Q H, XU L, DONG Y, et al. Plasma Galectin-3 is associated with progression from paroxysmal to persistent atrial fibrillation[J].BMC Cardiovasc Disord,2021,21(1):226. [5] ZHANG G W,XIAO M C,ZHANG L L, et al. Association of serum chemerin concentrations with the presence of atrial fibrillation[J].Ann Clin Biochem,2017,54(3):342-347. [6] 许继成,公永太.心脏脂肪组织与心房颤动机制的研究[J].中国心血管杂志,2019,24(1):83-85. [7] 张玮艺,余苹,张潇潇,等.2016年欧洲心脏病学会心房颤动管理指南(节选)(二)[J].中国卒中杂志,2017,12(5):446-452. [8] 杨华,孟利民,信栓力,等.心房颤动患者血清趋化素水平与心房纤维化程度的相关性[J].临床荟萃,2020,35(3):206-210. [9] 许承志,崔惠康,邓涛,等.达比加群酯胶囊联合替格瑞洛片治疗老年心房颤动合并不稳定型心绞痛患者的临床研究[J].中国临床药理学杂志,2022,38(9):891-894. [10] 李庆勇,袁向珍,汤宝鹏,等.心房颤动患者血清TGF-β1、Omentin-1、Gal-3水平变化及与心房纤维化的关系[J].中国循证心血管医学杂志,2021,13(5):554-557. [11] 朱浩杰,闻松男,邓家龙,等.半乳糖凝集素-3与阵发性心房颤动患者心房晚电位指标的相关性及射频消融术后复发预测[J].心肺血管病杂志,2019,38(10):1012-1016. [12] 李钰珑,曾显阁,丁唯可.心房心肌纤维化与冠脉搭桥术患者心房颤动及Gal-3的相关性[J].实用中西医结合临床,2020,20(13):112-114. [13] 杨海涛,赵丹清,王婷,等.内脂素与射频消融术后心房颤动复发的相关性研究[J].中国心血管杂志,2021,26(2):155-158. [14] 杨华,孟利民,信栓力,等.趋化素及可溶性ST2对阵发性心房颤动射频消融术后复发的预测价值[J].中国心血管杂志,2020,25(6):564-567.
2024, Vol. 41 
